Download MendeleyDual Protein Farnesyltransferase-Geranylgeranyltransferase-I Inhibitors as Potential Cancer Chemotherapeutic Agents.
DeSolms, S.J., Ciccarone, T.M., MacTough, S.C., Shaw, A.W., Buser, C.A., Ellis-Hutchings, M., Fernandes, C., Hamilton, K.A., Huber, H.E., Kohl, N.E., Lobell, R.B., Robinson, R.G., Tsou, N.N., Walsh, E.S., Graham, S.L., Beese, L.S., Taylor, J.S.(2003) J Med Chem 46: 2973-2984
- PubMed: 12825937
- DOI: https://doi.org/10.1021/jm020587n
- Primary Citation of Related Structures:
1MZC - PubMed Abstract:
A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.
Organizational Affiliation:
Departments of Medicinal Chemistry and Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
